Cartesian Reports Durable Descartes-08 Retreatment Data in MG
FREDERICK, Md. — September 29, 2026 Cartesian Therapeutics announced additional retreatment data from its Phase 2 program evaluating Descartes-08,...
Duchenne muscular dystrophy
Advertisement
Cognition Therapeutics Schedules FDA Type C Meeting for Zervimesine
PURCHASE, N.Y. — September 29, 2026 Cognition Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) Division...
JCR Gains Japan Orphan Drug Designation for Givinostat
HYOGO, Japan — September 28, 2026 JCR Pharmaceuticals Co., Ltd. announced that Japan’s Ministry of Health, Labour and Welfare...
Sarepta to Present Neuromuscular Portfolio Data at NMSG 2026
CAMBRIDGE, Mass. — September 24, 2026 Sarepta Therapeutics, Inc. announced that it will present seven posters covering its neuromuscular...
Capricor to Present Deramiocel HOPE-3 Data at WMS 2026
SAN DIEGO, Calif. — September 17, 2026 Capricor Therapeutics announced that 24-month data from the HOPE-3 Phase 3 trial...
Advertisements
Novartis Reports Phase III HARBOR Setback for Del-desiran
BASEL — September 8, 2026 Novartis announced that its global Phase III HARBOR study of delpacibart etedesiran (del-desiran) in...
Dyne Therapeutics Advances Four DMD Exon-Skipping Candidates
Waltham, Mass., September 3, 2026 Dyne Therapeutics announced that it will present new preclinical data supporting the development of...
NewBiologix Partners With Synastra on DMD Gene Therapy Manufacturing
LAUSANNE, Switzerland, September 2, 2026 NewBiologix S.A. has entered into an agreement with Synastra Biotechnology Inc. to develop a...
Capricor Advances Deramiocel as FDA Review Continues
SAN DIEGO, August 13, 2026 Capricor Therapeutics continues to advance Deramiocel (CAP-1002) for Duchenne muscular dystrophy (DMD) as the...
Ractigen Therapeutics Closes $31M Financing to Advance saRNA Pipeline
NANTONG, China, July 29, 2026 Ractigen Therapeutics has successfully closed a financing round exceeding $31 million (over RMB 200...
Advertisement
